Published in Blood Weekly, December 18th, 2008
"Alemtuzumab had minimal direct cytotoxicity but caused significant complement dependent cytotoxicity...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.